Serum sample quality determination
AssigneeSiemens Healthcare Diagnostics Inc.
InventorArthur Babson
Life of this patent
Estimating the term…
Loading patent…
AssigneeSiemens Healthcare Diagnostics Inc.
InventorArthur Babson
Estimating the term…
A method and device for measuring HIL levels in blood serum samples that are disposed in an automated, clinical chemistry analyzer. The device probe can be attached adjacent to a pipette or sample probe of the analyzer and includes fiber optic bundles and a light-reflecting surface. A cutaway portion is provided between the ends of each of the fiber optic bundles and the light-reflecting surface. One of the four fiber optic bundles is optically coupled to a light-emitting source. Each of the other three fiber optic bundles collects and filters reflected light from the reflecting surface. The light filters correspond to the optimal absorption wavelengths for one of hemoglobin, bilirubin, and triglycerides. A light intensity-measuring device is optically coupled to each of the three fiber optic bundles, to measure the intensity of the filtered, reflected light. A processing device receives output data signal from the light intensity-measuring devices; stores the data; and calculates whether a serum sample has elevated levels of one or more of HIL.
A blood serum screening device for use with an automated, clinical chemistry analyzer, the device comprising:
A method for measuring levels of hemoglobin, bilirubin, and triglycerides in a blood serum sample and for determining whether the measured levels exceed pre-established threshold levels for one or more of hemoglobin, bilirubin, and triglycerides, the method comprising:
Dependencies are inferred from the claim text.